New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
10:00 EDTJBT, ICPT, YUM, MCD, DNDN, BERY, OVSCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Dendreon (DNDN) initiated with a Buy at Needham... OvaScience (OVSC) initiated with an Outperform at Leerink... Intercept Pharmaceuticals (ICPT) initiated with a Buy at BofA/Merrill... Berry Plastics (BERY) initiated with an Outperform at Wells Fargo... McDonald's (MCD) initiated with a Buy at Davenport... Yum! Brands (YUM) initiated with a Buy at Davenport... JBT Corporation (JBT) initiated with a Buy at Sidoti.
News For DNDN;OVSC;BERY;ICPT;MCD;YUM;JBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 27, 2015
08:45 EDTICPTIntercept opportunity may be questioned after Genfit data, say Leerink
Subscribe for More Information
08:07 EDTICPTIntercept price target raised to $400 from $300 at Deutsche Bank
Subscribe for More Information
March 26, 2015
17:16 EDTMCDMcDonald's new strategy to create upside, says UBS
Subscribe for More Information
15:07 EDTICPTIntercept's FLINT data more convincing than Gefit data, says RBC Capital
Subscribe for More Information
14:45 EDTICPTIntercept's risk/reward remains favorable, says Citigroup
Subscribe for More Information
13:04 EDTICPTIntercept rallies after GENFIT announces NASH study results
GENFIT announced topline results of the phase 2 GOLDEN-505 trial in NASH. It stated, "Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint. With correction for this baseline severity and site heterogeneity by a standardized statistical analysis, GFT505 120mg meets the primary endpoint: Reversal on NASH without worsening of fibrosis, as detailed below." Treatment with GFT505 provides a significant beneficial effect on the primary endpoint in the global randomized population, where patients without an end of treatment biopsy were considered as non-responders, GENFIT added. The primary endpoint was also achieved in the evaluable population of patients who underwent both baseline and end of study liver biopsies. Shares of Intercept, which is also developing a NASH treatment, jumped 7%, or $18.06 to $278.70.
12:56 EDTICPTIntercept jumps after Genfit says NASH drug missed endpoint in Phase 2 study
Subscribe for More Information
March 25, 2015
16:55 EDTICPTOrbiMed Advisors lowers stake in Intercept to 5.64% from 7.0%
March 24, 2015
14:00 EDTMCDMorgan Stanley says survey results positive for Chipotle, mixed for McDonald's
Subscribe for More Information
05:49 EDTYUMStocks with implied volatility movement; LL YUM
Subscribe for More Information
March 23, 2015
12:52 EDTMCDMcDonald's calls active on investor letter
Subscribe for More Information
10:37 EDTYUMYum! Brands March weekly calls active amid renewed spin-off speculation
Yum! Brands March weekly 79 and 80 calls are active on total call volume of 10,500 contracts (500 puts) amid renewed spin-off speculation. March weekly call option implied volatility is at 30, April is at 23, May is at 26; compared to its 26-week average of 22 according to Track Data. Active call volume suggests traders taking large positions for upside price movement.
10:19 EDTYUMRumor: Yum! Brands up amid renewed spin-off speculation
Subscribe for More Information
10:12 EDTMCDGlenview said McDonald's could unlock $20B in value with REIT, Bloomberg reports
Subscribe for More Information
07:22 EDTICPTIntercept price target raised to $265 from $205 at Leerink
Subscribe for More Information
March 20, 2015
16:00 EDTMCDOptions Update; March 20, 2015
Subscribe for More Information
09:24 EDTICPTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ctrip.com (CTRP), up 20.1%... Rally Software (RALY), up 17.3%... Nike (NKE), up 5.2%... Darden Restaurants (DRI), up 4.3%... Cheetah Mobile (CMCM), up 3.6%. ALSO HIGHER: Prothena (PRTA), up 40.2% after reporting positive results from Phase 1 study of PRX002... Viggle (VGGL), up 26.9% after confirming receipt of offer from chairman and CEO Robert Sillerman... Intercept Pharmaceuticals (ICPT), up 8.5% after announcing new data analyses from FLINT trial... Biogen Idec (BIIB), up 9.7% after presenting positive interim results from study of aducanumab... Pier 1 Imports (PIR), up 5.2% after being upgraded to Outperform from Perform at Oppenheimer... JinkoSolar (JKS), up 2.8% after announcing that it will supply 75 MWdc of its PV solar modules to Red Horse 2 project and following a strategic collaboration agreement with DuPont (DD). DuPont is up just under 1%. DOWN AFTER EARNINGS: AK Steel (AKS), down 6.8%... Youku Tudou (YOKU), down 4.9%... Tiffany (TIF), down 3.3%. ALSO LOWER: Macerich (MAC), down 7.7% after Simon makes $95.50 per share "best and final" offer.
06:02 EDTICPTIntercept announces new data analyses from FLINT trial
Subscribe for More Information
March 19, 2015
13:07 EDTICPTIntercept to host analyst and investor meeting
Subscribe for More Information
March 18, 2015
09:00 EDTICPTIntercept price target raised to $344 from $258 at RW Baird
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use